Cargando…

Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.

Cardiac function was evaluated in 86 breast cancer patients after standard chemotherapy, followed by ablative chemotherapy and chest irradiation. One patient died of subacute heart failure 3 months after ablative chemotherapy. At a minimum of 1 year's follow-up (range 1-11 years) left vertricul...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Graaf, H., Dolsma, W. V., Willemse, P. H., van der Graaf, W. T., Sleijfer, D. T., de Vries, E. G., Mulder, N. H.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1997
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228075/ https://www.ncbi.nlm.nih.gov/pubmed/9328157

Ejemplares similares

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.
por: Sleijfer, S., et al.
Publicado: (1996)

Cisplatin in breast cancer.
por: Willemse, P., et al.
Publicado: (1993)

Guideline adherence for early breast cancer before and after introduction of the sentinel node biopsy
por: Schaapveld, M, et al.
Publicado: (2005)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect.
por: Sleijfer, S., et al.
Publicado: (1995)

Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy
por: Mourits, M J, et al.
Publicado: (2002)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

Dosimetric consequences of the shift towards computed tomography guided target definition and planning for breast conserving radiotherapy
por: van der Laan, Hans Paul, et al.
Publicado: (2008)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

A new in vitro assay for quantitation of chemotherapy-induced mucositis.
por: Wymenga, A. N., et al.
Publicado: (1997)

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1990)

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1992)

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
por: Gietema, J. A., et al.
Publicado: (1995)

Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation
por: Schröder, C P, et al.
Publicado: (2001)

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
por: Kroesen, B. J., et al.
Publicado: (1994)

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
por: Veldhuis, G. J., et al.
Publicado: (1997)

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
por: de Vries, E. G., et al.
Publicado: (1993)

Editorial: Cardiotoxicity induced by radiotherapy and/or chemotherapy after cancer treatment
por: Boerma, Marjan, et al.
Publicado: (2022)

The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands
por: Schaapveld, Michael, et al.
Publicado: (2007)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

A Pilot Study of Cardiac MRI in Breast Cancer Survivors After Cardiotoxic Chemotherapy and Three-Dimensional Conformal Radiotherapy
por: Bergom, Carmen, et al.
Publicado: (2020)

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014)

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
por: Biesma, B., et al.
Publicado: (1992)

Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer
por: Alıcı, Hayri, et al.
Publicado: (2015)

Aging, cardiotoxicity, and chemotherapy
por: Bocchi, Edimar Alcides, et al.
Publicado: (2019)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity
por: Sivapackiam, Jothilingam, et al.
Publicado: (2020)

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
por: Gietema, J. A., et al.
Publicado: (1993)

Upregulation of Endothelin-1 May Predict Chemotherapy-Induced Cardiotoxicity in Women with Breast Cancer
por: Krishnarao, Krithika, et al.
Publicado: (2022)

Pediatric Chemotherapy Drugs Associated With Cardiotoxicity
por: Hitawala, Gazala, et al.
Publicado: (2021)

Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
por: Withoff, S., et al.
Publicado: (1996)

Cardiotoxicity due to chemotherapy for breast cancer: The dark side of the moon
por: Peruzzi, Mariangela, et al.
Publicado: (2015)

Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study
por: Gavila, J., et al.
Publicado: (2016)

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy
por: Hannemann, J, et al.
Publicado: (2006)

Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients
por: Hasan, Diya, et al.
Publicado: (2021)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

Global longitudinal strain: an early marker for cardiotoxicity in patients treated for breast cancer
por: van der Linde, D., et al.
Publicado: (2022)

Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
por: Gillespie, Hamilton S, et al.
Publicado: (2011)

Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention
por: CSAPO, MELINDA, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fdk1d5oq8jbd5vk26qa1es99p3